Under the scope: RAD 140

[01dragonslayer]

It is a third generation SARM, being investigated by Radius Health with the aim of serving for TRT and as a treatment for prostate or breast cancer with the fewest possible side effects.

Pros​

• Has a potency similar to testosterone, mg for mg has a great potency.
• Has a half-life of 60 hours (contrary to the 14 that are often said).
• Has a high affinity for androgen receptors, increasing the oxidation of fatty acids.
• Does not aromatize or convert to DHT therefore it has no androgenic capacity.
• Raises transaminases much less than the rest of the less potent SARMS.
• Basal metabolic rate increases.
• Has a neuroprotective effect (increases the feeling of well-being and libido).

Cons​

• By increasing the dose it loses the selectivity characteristic of SARMS.
• The lipid profile worsens.
• Elevation of transaminases.

Summary​

It is a very powerful SARM with a lot of different benefits and few side effects, doses of 14-50mg are recommended depending on weight and goals and its half-life is 60 hours.

 

[BigTex]

Seems Radius Health (2017-2020) initiated Phase 1 trials in September 2017 for hormone receptor-positive breast cancer. After completing the trials, Radius divested RAD-140 to Ellipses Pharma, completing their exit from oncology. RAD-140 was NOT being developed for TRT (testosterone replacement therapy). The biggest problem is it doesn't actually replace testosterone. Testosterone is needed to optimize many of our hormones. Unfortunately, it does suppress testosterone. Seen guys try this for TRT, and it was a disaster.

https://ellipses.life/wp-content/uploads/2020/12/Press-Release_Radius-Health-Divests-RAD-140-Program-to-Ellipses-Pharma.pdf

Ellipses Pharma (2020-Present): Renamed the compound "vosilasarm" (also known as EP0062). They are currently running an active Phase 1/2 trial (NCT05573126) that is recruiting patients. This study will evaluate vosilasarm-ep0062 as monotherapy and in combination in patients with advanced or metastatic ARHER2-ER-breast cancer, specifically for AR+/ER+/HER2- breast cancer.

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Clinical Research Trial Listing

The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

www.centerwatch.com

https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.1057